Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
Van Den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Ghesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F. Van Den Neste E, et al. Among authors: belhabri a. Haematologica. 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554. Epub 2018 Jan 19. Haematologica. 2018. PMID: 29351986 Free PMC article. Clinical Trial.
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, Reman O, Dombret H, Dhedin N, Michallet M, Fière D, Archimbaud E. Belhabri A, et al. Hematol J. 2002;3(1):49-55. doi: 10.1038/sj.thj.6200141. Hematol J. 2002. PMID: 11960396 Clinical Trial.
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E, Ségura-Ferlay C, Ghesquières H, Chassagne-Clément C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C. Nicolas-Virelizier E, et al. Among authors: belhabri a. Hematol Oncol. 2015 Mar;33(1):1-8. doi: 10.1002/hon.2130. Epub 2014 Feb 5. Hematol Oncol. 2015. PMID: 24496668
[Association of lymphoma and granulomatosis: A case series].
de Charry F, Sadoune K, Sebban C, Rey P, de Parisot A, Nicolas-Virelizier E, Belhabri A, Ghesquières H, Ninet J, Faurie P. de Charry F, et al. Among authors: belhabri a. Rev Med Interne. 2016 Jul;37(7):453-9. doi: 10.1016/j.revmed.2015.10.344. Epub 2015 Nov 25. Rev Med Interne. 2016. PMID: 26611429 French.
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G, Ferlay C, Nicolas-Virelizier E, Rey P, Ducray F, Jouanneau E, Faurie P, Belhabri A, Sunyack MP, Chassagne-Clément C, Thiesse P, Sebban C, Biron P, Blay JY, Ghesquières H. Fossard G, et al. Among authors: belhabri a. Eur J Cancer. 2017 Feb;72:12-19. doi: 10.1016/j.ejca.2016.10.036. Epub 2016 Dec 22. Eur J Cancer. 2017. PMID: 28012348
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921).
Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Zittoun R, Hess U, Anak O, Beeldens F, Willemze R, de Witte T. Oosterveld M, et al. Among authors: belhabri a. Leukemia. 2003 May;17(5):859-68. doi: 10.1038/sj.leu.2402897. Leukemia. 2003. PMID: 12750698
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study. Attal M, et al. N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750. N Engl J Med. 2017. PMID: 28379796 Free PMC article. Clinical Trial.
Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.
Dony A, Belhabri A, Bertrand Y, Sebban C, Cony-Makhoul P, Sobh M, Rogasik M, Salles G, Anglaret B, Freycon C, Corm S, Faurie P, Cornillon J, Michallet AS, Chassagne-Clément C, Berger F, Ray-Coquard IL. Dony A, et al. Among authors: belhabri a. J Adolesc Young Adult Oncol. 2019 Dec;8(6):684-696. doi: 10.1089/jayao.2019.0016. Epub 2019 Aug 14. J Adolesc Young Adult Oncol. 2019. PMID: 31411521
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).
Michallet M, Thomas X, Vernant JP, Kuentz M, Socié G, Espérou-Bourdeau H, Milpied N, Blaise D, Rio B, Reiffers J, Jouet JP, Cahn JY, Bourhis JH, Lioure B, Leporrier M, Sotto JJ, Souillet G, Sutton L, Bordigoni P, Dreyfus F, Tilly H, Gratecos N, Attal M, Leprise PY, Déméocq F, Michel G, Buzyn A, Delmas-Marsalet B, Bernaudin F, Ifrah N, Sadoun A, Guyotat D, Cavazzana-Cavo M, Caillot D, De Revel T, Vannier JP, Baruchel A, Fegueux N, Tanguy ML, Thiébaut A, Belhabri A, Archimbaud E. Michallet M, et al. Among authors: belhabri a. Bone Marrow Transplant. 2000 Dec;26(11):1157-63. doi: 10.1038/sj.bmt.1702690. Bone Marrow Transplant. 2000. PMID: 11149725
47 results